Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...